From November 6 to 8, 2026, a delegation led by the Head of the Advisory Committee to the Director-General of Thailand’s Ministry of Public Health, accompanied by representatives of Krirk University visited HighTide Therapeutics. The Company’s executive team warmly welcomed the delegation and accompanied them on a tour of its headquarters, where they were introduced to HighTide’s development history, business strategy, R&D achievements, and global operations. The visit provided an opportunity for the delegation to gain deeper insight into HighTide Therapeutics’ global R&D activities, while also serving as a constructive dialogue between the two sides on chronic disease prevention and treatment, as well as opportunities for cross-border innovation collaboration.
Leveraging Global R&D Capabilities to Expand Opportunities for Innovation Collaboration
During a meeting with the delegation, HighTide Therapeutics’ executive team provided an overview of the Company’s development journey, product portfolio, and business progress. The discussion also highlighted the Company’s focus on cardiovascular–kidney–metabolic (CKM) diseases and its strategy of developing multifunctional, multi-targeted therapies to address unmet medical needs in this area.
HighTide Therapeutics presented its global development strategy for its lead candidate HTD1801, provided updates on clinical studies across multiple CKM-related indications, and introduced its global intellectual property portfolio. The Company also shared how it leverages international expertise and resources to advance its global R&D efforts. The delegation discussed the research progress and future development plans with the HighTide Therapeutics team, and expressed their recognition of the Company’s R&D approach, which emphasizes independent innovation and ongoing global clinical validation.
The Company also shared its experience in combining traditional Chinese natural products with modern pharmaceutical research and development technologies to create innovative medicines. The two sides exchanged perspectives on China’s innovative pharmaceutical landscape, the modernization of natural products, and the international development of innovative medicines. Discussions also explored how modern scientific research can unlock the value of innovation and how research findings can be better aligned with clinical needs in different countries.
The delegation expressed their recognition of HighTide Therapeutics’ China-based, globally oriented R&D strategy. They showed particular interest in the potential of HTD1801’s “one drug, multiple efficacies” approach to deliver comprehensive therapeutic benefits, and expressed interest in exploring opportunities for collaboration in clinical research and academic exchange, aiming to better address local healthcare needs through innovative therapies.
Showcasing China’s Innovation Through Global Research Evidence
Following the meeting, the delegation toured HighTide Therapeutics’ headquarters and its scientific achievements exhibition area, where they were introduced to the Company’s latest R&D progress.
The exhibition showcased research published in international scientific journals and data presented at international scientific conferences. Collectively, these materials illustrate the growing body of evidence supporting HTD1801’s development across CKM-related diseases, and trace the Company’s evolution from China-based R&D to pursuing global clinical research and validation.
During the tour, the delegation listened to the presentations and spoke positively about the Company’s research achievements in chronic diseases. They also expressed interest in the research prospects of innovative therapies for addressing the complex treatment needs of patients with multiple coexisting conditions, and looked forward to further exchanges to deepen understanding of the relevant scientific evidence and potential clinical value.
Building Mutual Trust Through Exchange and Bringing Innovation Across Borders
This visit provided the delegation with a deeper understanding of HighTide Therapeutics and China’s approach to innovative drug development. It also laid a solid foundation for both sides to share experience, strengthen mutual trust, and explore future collaboration. Both sides expressed their commitment to maintaining close communication, continuing discussions in areas of shared interest, and working together to make innovative treatments available to more patients.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across CKM diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
For more information, please visit www.hightidetx.com. Contact: pr@hightidetx.com